ClearPoint Neuro, Inc. (CLPT)

Clearpoint Neuro's stock (CLPT) has trended upwards by 73.13% in the past six months. As of October 24, 2025, the share price was $24.74, an increase of 89.72% from $13.04 on October 25, 2024. Recent events include CLPT expanding into robotic systems supporting cell and gene therapies, Paul Larson joining as Chief Medical Officer in January 2026, and a new major risk regarding share price stability being noted. The company reported its second-quarter 2025 earnings, with EPS missing analyst expectations but total revenue increasing by 17%. Stifel Nicolaus raised its price target for Clearpoint Neuro from $8.00 to $9.00 and issued a "buy" rating. Lane Generational LLC increased its holdings in Clearpoint Neuro by 6.8%, while CEO Joseph Burnett sold 26,463 shares of Clearpoint Neuro stock. Strategic partnerships and global expansion were highlighted as aiming to boost revenue and earnings. ClearPoint Neuro reported record revenues and significant growth in its Third Quarter 2024 Earnings Call.

The provided search results do not explicitly detail the demand seasonality for Clearpoint Neuro, Inc.'s products and services. Demand might be influenced by factors such as hospital budgets, clinical trial schedules, regulatory approvals, and the prevalence of neurological conditions. The company aims for double-digit hospital placements annually, indicating a continuous demand rather than seasonal peaks or troughs.

Clearpoint Neuro, Inc. is a medical technology company specializing in MRI-guided platforms for minimally invasive neurosurgical procedures, particularly for cell and gene therapy delivery. The company develops and commercializes an MRI-guided therapy platform for precise navigation to the brain and spine. Its key products include the ClearPoint system, ClearPoint Array Neuro Navigation System, and the PRISM laser therapy system. The 3.0 navigation software has been well-received and is available in numerous sites across the United States.

Clearpoint Neuro, Inc. primarily operates in the United States. The company is also engaged with healthcare and research centers across North America, Europe, Asia, and South America, providing solutions for direct Central Nervous System (CNS) delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

Clearpoint Neuro has a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.50. The company's MarketRank™ score indicates it performed better than 31% of companies evaluated in the medical sector. The 3.0 navigation software has been "very well received" since its FDA clearance. Strategic partnerships and global expansion efforts are aimed at boosting revenue and earnings, which can positively influence brand perception.

Clearpoint Neuro (NASDAQ: CLPT) is owned by a mix of institutional shareholders, insiders, and retail investors, with retail investors holding the largest share at 49%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Geode Capital Management, Llc, State Street Corp, Morgan Stanley, Brown Advisory Inc, and Essex Investment Management Co Llc. The largest individual shareholder is Bruce C. Conway, an insider, owning 4.00 million shares. CEO Joseph Burnett directly holds 0.9% of the total shares outstanding.